ADPT compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

ADPTAdaptive Biotechnologies Corp

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

ADPTAdaptive Biotechnologies Corp

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

ADPT: latest quarter is a loss; flow not drawable.Method ›

Price

rebased to 0%

ADPT, solidAMGN, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ADPT 6

PFEPfizercustomer

ILMNIlluminasupplier

—Fred Hutchinson Cancer Research Centerunlistedsupplier

—Genentechunlistedcustomer

2 more · ADPT chain ›

Shared 0

No shared counterparties.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

8 more · AMGN chain ›

ADPTAdaptive Biotechnologies Corp

26.62▼−5.51%· post 26.60

Mkt cap$4.3BRevenue$72MQ2 FY26Revenue$277MFY25

AMGNAmgen Inc

466.31▲+1.21%· post 466.40

ClosedOct 30 '26

Mkt cap$251.9BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

Compare

ClosedOct 30 '26

ADPTAdaptive Biotechnologies Corp

AMGNAmgen Inc

26.62▼−5.51%post 26.60

Price

466.31▲+1.21%post 466.40

$4.3B

Mkt cap

$251.9B

Q2 FY26$72M

Revenue

$10.1BQ2 FY26

FY25$277M

Revenue

$36.8BFY25

ADPT26.62▼−5.51%vsAMGN466.31▲+1.21%ClosedOct 30 '26